Experimental CAR-T therapy targets Hard-to-Treat brain cancer
Disease control
Recruiting now
This pilot study is testing a new treatment called Anbal-cel for people with relapsed or refractory primary or secondary central nervous system lymphoma. Anbal-cel is a CAR-T cell therapy made from the patient's own immune cells. The study will enroll 12 participants to see if th…
Phase: PHASE2 • Sponsor: Hyungwoo Cho • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC